Selvita sees signs of biotech market rebound
20:06
Selvita, a biotech company, foresees a challenging year in 2023 but has identified initial signs of market recovery. They aim for double-digit growth in their backlog by 2024. The company is using this year to bolster its sales position as a foundation for future expansion.
In 2023, Selvita reported a backlog of PLN 318.8 million, representing a 3% increase from the…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
